HVO Hvivo Plc

TIDMHVO

RNS Number : 0179Z

hVIVO plc

23 May 2016

For immediate release 12.00pm: 23 May 2016

HVIVO PLC

("hVIVO" or the "Company")

Result of Annual General Meeting

hVIVO plc (AIM: RVG), the pioneer of human models of disease, is pleased to announce that all resolutions proposed at its Annual General Meeting, held at 10.00am on 23 May 2016, were duly passed.

For further information please contact:

hVIVO plc +44 207 756 1300

Kym Denny (Chief Executive Officer)

Graham Yeatman (Chief Financial & Business Officer)

Media Enquiries +44 203 021 3933 / +44 7854 979 420

Colin Paterson (Director of Marketing, Communication and Public Relations)

Numis Securities Limited +44 207 260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black / Michael Burke (Corporate Broking)

Notes to Editors:

hVIVO plc ("hVIVO") is a life sciences company pioneering a technology platform of human disease models to accelerate drug discovery and development in respiratory and infectious diseases, including flu, RSV, asthma and common cold. hVIVO has commercialised four disease models, successfully enrolled over 2,000 subjects and conducted over 40 product validation studies for a wide range of industry, government and academic clients and collaborators.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGAKNDNKBKDQPB

(END) Dow Jones Newswires

May 23, 2016 07:00 ET (11:00 GMT)

Hvivo (LSE:HVO)
Historical Stock Chart
From Jun 2024 to Jul 2024

Hvivo (LSE:HVO)
Historical Stock Chart
From Jul 2023 to Jul 2024